

## **Our commitment to transparency in financial relationships with healthcare professionals and healthcare organisations**

Novo Nordisk is committed to driving change in diabetes, obesity and other chronic diseases. This includes engaging with healthcare professionals, healthcare organisations and patients.

Novo Nordisk supports transparency and is committed to compliance with disclosing our financial relationships related to our collaborations with the medical community as required by our industry guidelines, namely the Irish Pharmaceutical Healthcare Association (IPHA) Code of Practice. We believe the transparency of financial relationships between those with whom we collaborate is very important to maintaining trust-based relationships with our patients and the public.

Please refer to the Patient Organisations Disclosure link on [www.novonordisk.ie](http://www.novonordisk.ie) for the transactions Novo Nordisk has made to Patient Organisations. This disclosure is published annually at the end of June and refers to the previous calendar year.

As a member of the Irish Pharmaceutical Healthcare Association (IPHA), Novo Nordisk is required to make public details of payments and transfers of value (ToV) or in kind made to Irish healthcare professionals and healthcare organisations in each calendar year. This ToV is published annually at the end of June on [www.transferofvalue.ie](http://www.transferofvalue.ie).

The Apis bull logo is a registered trademark owned by Novo Nordisk A/S  
IE25NNG00026, June 2025

